Leveraging Mitochondria
to Change Lives

MINING THE MITOCHONDRIAL GENOME

CohBar is the leader in discovering and developing novel therapeutics sourced from the mitochondrial genome. Our scientists focus on discovering novel peptides encoded in the mitochondrial DNA and generated thousands of novel analogs. We have a robust pipeline of clinical and pre-clinical programs, all derived from our discovery engine called Mito+, and we have established a robust and growing IP portfolio with 15 issued patents and over 65 patent filings.

About CohBar

Powered By Evolution

Our approach exploits the longstanding symbiotic relationship between the mitochondria and human cells, enabling us to take advantage of millennia of evolutionary pressure. Further, by focusing on analogs of naturally occurring peptides, we expect our product candidates to have superior safety profiles, both decreasing the development risk for our programs and providing patients and physicians with treatment options with fewer side effects.

Even though our peptides are sourced from the mitochondrial genome, certain of these peptides produce effects that are not limited to local regulation within the mitochondria, but may play important signaling and regulatory roles in diverse biological pathways unrelated to what have historically been considered mitochondrial functions. Many mitochondria companies focus on genetic diseases caused by mitochondrial defects or abnormalities, but our focus is on larger unmet medical needs.

Our Approach

PATIENTS ARE AT THE CORE OF WHAT WE DO

With our know-how and expertise in mitochondrial science, our approach enables us to target large unmet medical needs in a wide range of conditions such as idiopathic pulmonary fibrosis (IPF), nonalcoholic steatohepatitis (NASH), obesity, and acute respiratory distress syndrome (ARDS).

Our Programs

Mito™ Technology Platform

We have discovered a number of novel peptide families that are structurally unique and have distinct mechanisms of action, providing us with multiple independent opportunities for success.

Our Pipeline
IPF and Other Fibrotic Diseases

CB5138-3 - IPF and Other Fibrotic Diseases

We are developing CB5138-3 for the treatment of IPF.  In August 2020, we presented data on the efficacy of CB5138 Analog peptides in preclinical models of IPF at the American Thoracic Society Virtual Annual Meeting. In a widely used therapeutic mouse model of IPF, CB5138-3 significantly reduced lung fibrosis, as evidenced by decreases in the Ashcroft Score, fibrosis-related changes in lung weight, collagen deposition in lung tissue and collagen secretion into lung fluid. 

CB5138-3 is currently in IND-enabling studies and we expect to file our IND in the second half of 2023 and commence a First-in-Human study shortly thereafter. While our initial indication is IPF, we are also studying CB5138 Analogs in preclinical models of other fibrotic diseases.

View Candidate
NASH and Obesity

CB4211 - NASH and Obesity

In 2021, we announced positive topline data from our Phase 1a/1b study of CB4211, which is under development for the treatment of NASH and obesity. This study met its primary endpoints as CB4211 was well-tolerated and appeared safe with no serious adverse events. Evaluation of the exploratory endpoints in the 1b portion of the trial showed significant reductions from baseline in key biomarkers of liver damage, ALT and AST, and in glucose levels in the CB4211 group compared to placebo after four weeks of treatment, with a trend towards lower body weight. In addition, there was a measurable reduction in the level of liver fat. 

CB4211 is a first-in-class therapeutic that is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial derived peptide (MDP). MOTS-c was discovered in 2012 by CohBar founder Dr. Pinchas Cohen and his academic collaborators and has been shown to play an important role in the regulation of metabolism. Consistent with our recent clinical data, CB4211 has demonstrated significant therapeutic potential in preclinical models of NASH and obesity.

View Candidate
ARDS, including COVID-19 Associated ARDS

CB5064 Analogs - ARDS, including COVID-19 Associated ARDS

CB5064 Analogs selectively activate the apelin receptor.  Apelin is a key signaling pathway known to be protective in animal models of ARDS, sepsis, stroke and thrombosis. In preclinical studies of ARDS, CB5064 Analogs demonstrated significant reductions in lung fluid accumulation, cytokine secretion, and neutrophil infiltration.

View Candidate
Our Discovery Efforts

Our Discovery Efforts

Utilizing our Mito+ technology platform, we employ a broad range of proprietary activity screens to assess the therapeutic potential of our novel peptides. Biological activity of peptides encoded within the mitochondrial genome is initially determined using assay formats which are highly predictive of human activity. Promising classes of peptides are then tested in secondary assay formats to determine mechanism of action and translation to human disease. Analog libraries of natural peptide classes with promising therapeutic potential are subsequently prepared and studied using in vitro and/or in vivo models to confirm their biological effects prior to the selection of a clinical candidate for further testing and ultimate entry into clinical trials.

Our Approach